Appendix 4E & Annual Report
Released
Released
Announcement PDF
Race Oncology Limited
Appendix 4E
Preliminary final report
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Race Oncology Limited
12 345 678 901
For the year ended 30 June 2025
For the year ended 30 June 2024
2. Results for announcement to the market
Revenues f rom ordinary activities
down
5.3% to
$
788,418
Loss f rom ordinary activities af ter tax attributable to the owners of
Race Oncology Limited
down
65.4% to
(4,787,258)
Loss f or the year attributable to the owners of Race Oncology
Limited
down
65.4% to
(4,787,258)
Dividends
There were no dividends paid, recommended or declared during the current f inancial period.
Comments
The loss f or the consolidated entity af ter providing f or income tax amounted to $4,787,258 (30 June 2024:
$13,819,336).
3. Net tangible assets
Net tangible assets per ordinary security
Reporting
period
Cents
7.76
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current f inancial period.
Previous period
There were no dividends paid, recommended or declared during the previous f inancial period.
7. Dividend reinvestment plans
Not applicable.
Previous
period
Cents
9.10
Race Oncology Limited
Appendix 4E
Preliminary final report
8. Details of associates and joint venture entities
Not applicable.
9. Foreign entities
Details of origin of accounting standards used in compiling the report:
On 6 October 2017, the Company incorporated a subsidiary in Belgium, Race Oncology, Company Number
0682664917. There were no signif icant f inancial transactions through the subsidiary f or the year ended 30 June
2025. On 18 June 2025, the Group dissolved its wholly owned subsidiary, Race Oncology SRL/BV, incorporated in
Belgium. The dissolution was completed in accordance with relevant corporate regulations, and the entity has ceased
operations.
10. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The f inancial statements have been audited and an unmodif ied opinion has been issued.
11. Attachments
Details of attachments (if any):
The Annual Report of Race Oncology Limited f or the year ended 30 June 2025 is attached.
12. Signed
Signed ___________________________
Peter Smith
Executive Director/Chair
Authorised for release by the Board.
Date: 26 August 2025
ASX: RAC
AT THE
HEART OF
CANCER CARE
Annual Report 2025
CORPORATE
DIRECTORY
Directors
Peter Smith Executive Director/Chair
Daniel Tillett Chief Executive Officer and Managing Director
Serge Scrofani Independent Non-Executive Director
Megan Baldwin Independent Non-Executive Director
Company secretary
Peter Webse
Registered office and principal
place of business
Level 36, Gateway, 1 Macquarie Place
Sydney NSW 2000
Ph: +61 2 8051 3043
Website: www.raceoncology.com
Auditor
Hall Chadwick WA
Securities exchange listing
Race Oncology Limited shares are listed on the Australian
Securities Exchange (ASX) (ASX code: RAC)
Share registry
Automic Group
Level 5, 126 Phillip Street
Sydney NSW 2000
Ph: 1300 288 664
Race Oncology Limited
ACN 149 318 749
CONTENTS
Chair Letter
2
2025 Key Highlights
4
Directors’ Report
6
Auditor’s Independence Declaration
21
Consolidated Statement of Profit or Loss
and Other Comprehensive Income
22
Consolidated Statement of Financial Position
23
Consolidated Statement of Changes in Equity
24
Consolidated Statement of Cash Flows
25
Notes to the Financial Statements
26
Consolidated Entity Disclosure Statement
47
Directors’ Declaration
48
Independent Auditor’s Report
49
Shareholder Information
54
Glossary
57
General information
The financial statements cover Race Oncology Limited as
a consolidated entity consisting of Race Oncology Limited
and the entities it controlled at the end of, or during, the
year. The financial statements are presented in Australian
dollars, which is Race Oncology Limited's functional and
presentation currency.
Race Oncology Limited is a listed public company limited
by shares, incorporated and domiciled in Australia.
A description of the nature of the consolidated entity's
operations and its principal activities are included in the
directors' report, which is not part of the financial statements.
The financial statements were authorised for issue, in
accordance with a resolution of directors, on 28 August
2025. The directors have the power to amend and reissue
the financial statements.
Annual Report 2025
1
CHAIR
LETTER
Dear Shareholders,
I am pleased to present Race
Oncology’s Annual Report for the
2024-2025 financial year (FY2025)
- a period marked by significant
clinical progress, strategic team
growth and development, and
rigorous financial stewardship.
RC220 clinical advancement
A cornerstone achievement this year was the initiation
of our Phase 1 clinical trial of RC220 in combination with
doxorubicin for patients with advanced solid tumours.
Following the submission of the ethics and regulatory
data package to the Bellberry Human Research Ethics
Committee (HREC) in December 2024, we received
ethics and regulatory approvals in early 2025. This
enabled the activation of trial sites at Southside Cancer
Care Centre in Miranda and Gosford & Wyong Hospitals
(Central Coast Local Health District, New South Wales),
with the first patient safely dosed on 30 April 2025.
Subsequently, on 18 June 2025, we announced that
the first patient had been dosed with the RC220 +
doxorubicin combination, with no treatment-related,
dose-limiting adverse side effects. This marked a
significant milestone in RC220’s progression.
The successful first dosing of RC220 is a very significant
milestone. Historically, it was the inability to deliver
the active drug intravenously that prevented this
otherwise safe and effective treatment from being
commercialised. RC220 has overcome that problem.
Post reporting period, we were pleased to announce
the expansion of the trial to Asia, with HREC approvals
to commence our Phase 1 clinical trial of RC220 in
combination with doxorubicin at the Prince of Wales
and Queen Mary Hospitals in Hong Kong.
2
Race Oncology Limited
We look forward to providing regular progress updates
on the trial as significant milestones continue to be met
over the coming months.
In March 2025, we announced the execution of a
contract with the Contract Research Organisation
(CRO), Emerald Clinical Trials (formerly George Clinical
International), to support the clinical development of
RC220 via outsourced trial related services, investigator
grants, and pass through costs for the RC220
Phase 2 trial.
Other clinical developments for Race through FY2025
included the successful completion of a Fat Mass
and Obesity-associated protein (FTO)-targeted
drug discovery program with Monash University’s
Fragment Platform (MFP). This program identified
39 molecular candidates that specifically bind to the
N6-methyladenosine (m6A) ribonucleic acid (RNA)
demethylase protein, FTO, providing valuable new
intellectual property (IP), aiding the development of
novel m6A RNA epigenetic pathway drugs. We also
announced that our investigator-sponsored Phase
1b/2 trial of RC110 in combination with clofarabine and
fludarabine (Bis/Clo/Flu) in relapsed or refractory (R/R)
acute myeloid leukaemia (AML) patients had been
successfully concluded after achieving its primary
endpoint for efficacy. We are grateful to Professor
Nagler and the patients and families that participated
in these trials as they provide compelling data in the
modern era.
Strengthening clinical leadership
We were delighted to announce the appointment of
distinguished oncologist, Professor Daniel Von Hoff to
Race’s Clinical Advisory Board in July 2024 to advise
on the clinical development of RC220. Dr Daniel D Von
Hoff, MD, FACP FASCO, FAACR is the Executive Vice
President of the Molecular Medicine Divisions and
Distinguished Professor at the Translational Genomics
Research Institute in Phoenix, Arizona and City of
Hope. Securing someone of the international calibre of
Professor Van Hoff is a major accomplishment for Race
and his expertise has been instrumental in accelerating
the clinical and commercial development of RC220.
In May 2025, we announced key senior clinical team
appointments to bolster our clinical development
capabilities. Dr Jose Iglesias succeeded Dr Michelle
Rashford as Chief Medical Officer (CMO). Dr Iglesias
is an internationally recognised pharmaceutical
executive with a distinguished career, spanning both
major and emerging pharmaceutical companies. His
appointment marks a significant addition to Race’s
clinical leadership team. Additionally, Dr Simon Fisher
was appointed as Vice President of Medical, a newly
created role. Dr Fisher brings more than 25 years of
pharmaceutical and clinical affairs experience, having
held leadership positions at major pharmaceutical firms
including Johnson & Johnson, Novartis, AstraZeneca,
and Bristol-Myers Squibb. In his short time with Race,
he has already played an instrumental role in guiding us
through our ambitious development plans.
Board renewal
In September 2024, long-serving Directors, Mary
Harney and Philip Lynch retired. I stepped into the role
of Executive Chair, and Dr Daniel Tillett moved from
Chief Executive Officer (CEO) to CEO and Managing
Director. We also welcomed Dr Serge Scrofani as an
Independent Non-Executive Director, bringing diverse
experience in global deal-making across mergers &
acquisitions (M&A) and licensing. Rounding out the
board, we welcomed Dr Megan Baldwin in December
2024 as an Independent Non-Executive Director,
bringing extensive experience in biotechnology and
clinical development.
The board renewal and new director appointments
have brought valuable expertise and fresh perspectives
to the company. These additions have strengthened
our governance, enhanced strategic decision-making,
guided our clinical program, and positioned us well for
future growth.
Strategic IP consolidation
In June 2025, we announced the termination of our
global IP license agreement with the City of Hope
National Medical Center. This decision followed senior
expert legal and IP advice that the license no longer
delivered value to our shareholders, given the future
costs required to maintain it. We are confident our IP
strategy affords very strong protection and we retain
full freedom to operate and utilise bisantrene in all
planned clinical and non-clinical applications.
Financial strength and research &
development investment
Our financial position remains robust. As of 30 June
2025, Race held cash and cash equivalents of $13.67
million. Notably, more than 83% of our Q4 2025
expenditure ($3.11 million) was directed toward research
and development (R&D) and drug manufacturing
activities, underscoring our commitment to advancing
our clinical programs. This prudent cash management
ensures we are funded for all announced clinical and
preclinical programs through CY2026.
Outlook
Looking ahead, Race Oncology is well-positioned to
continue its mission of being at the heart of cancer care.
We remain focused on advancing our RC220 clinical
trials, exploring strategic partnerships, and delivering
value to our shareholders.
On behalf of the Board, I extend our gratitude to our
dedicated team, partners, patients, and shareholders
for your ongoing support.
Sincerely,
Dr Peter Smith
Executive Chair
Annual Report 2025
3
2025 KEY
HIGHLIGHTS
2 July 2024
2 September 2024
4 October 2024
21 November 2024
Race announced the
appointment of Professor
Daniel Von Hoff to Race’s
Clinical Advisory Board.
Race announced a newly
appointed board to
support the Company
through its next phase
of development. This
included Mr Phil Lynch
and Ms Mary Harney’s
retirements from the
Board, Dr Pete Smith
being appointed
Executive Chair and Dr
Daniel Tillett moving
from CEO to CEO and
Managing Director.
Dr Serge Scrofani
was appointed as an
Independent NonExecutive Director.
Race submitted a
provisional patent
application for the RC220
bisantrene formulation,
which would provide
exclusive IP protection of
the RC220 formulation
until October 2044.
Race announced that
it had successfully
completed an FTOtargeted drug discovery
program at MFP,
identifying 39 unique
protein-binding FTO
molecules.
5 December 2024
17 December 2024
5 March 2025
7 March 2025
Race announced the
submission of the ethics
and regulatory package
to Bellberry HREC for
approval of a Phase 1
clinical trial of RC220 at
the Australian lead site,
Southside Cancer Care
Centre (Miranda, NSW).
Race received $5,254,557
via the R&D Tax Incentive
from the ATO for FY2025.
Race announced the
execution of a contract
with the CRO, George
Clinical International (now
Emerald Clinical Trials),
to support the clinical
development of RC220
bisantrene.
S&P Dow Jones Indices
announced the addition
of Race Oncology to
the All Ordinaries Index
effective from 24 March
2025.
4
Race Oncology Limited
27 March 2025
31 March 2025
22 April 2025
1 May 2025
Race announced the
initiation of Southside
Cancer Care Centre
in Miranda, NSW, in
preparation for the
commencement of
patient enrolment for its
Phase 1 clinical trial of
RC220 in combination
with doxorubicin
in advanced solid
tumours patients.
Race announced that
it has received HREC
approval from Bellberry
to commence its RC220
Phase 1 clinical trial at
Gosford and Wyong
Hospitals (Central Coast
Local Health District).
Race announced the
activation of the second
site for patient enrolment
for its Phase 1 clinical trial
of RC220, in combination
with doxorubicin, in
patients with advanced
solid tumours at the
Central Coast Local
Health District.
Race announced the
successful and safe
dosing of the first patient
with RC220 in its Phase 1
clinical trial in advanced
solid tumours.
5 May 2025
19 June 2025
Race announced the
appointments of Dr Jose
Iglesias as CMO and Dr
Simon Fisher to Vice
President of Medical.
Race announced0 the
successful and safe
combination dosing of
the first patient with
RC220 plus doxorubicin
in its Phase 1 clinical trial
in advanced solid tumour
patients.
FY25 SAW THE MAJOR
MILESTONE OF THE
SUCCESSFUL AND
SAFE TREATMENT OF
THE FIRST PATIENT
WITH RC220 & RC220
IN COMBINATION WITH
DOXORUBICIN IN OUR
PHASE 1 CLINICAL
TRIAL IN PATIENTS
WITH ADVANCED
SOLID TUMOURS
Annual Report 2025
5
Race Oncology Limited
Directors' report
30 June 2025
Directors’ Report
The directors present their report, together with the financial statements, on the consolidated entity (referred to
hereafter as the 'consolidated entity') consisting of Race Oncology Limited (referred to hereafter as the 'Company' or
'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2025.
Information on directors
The following persons were directors of Race Oncology Limited during the whole of the financial year and up to the
date of this report, unless otherwise stated:
Peter Smith
Qualifications
Experience
Interest in shares and options
Directorships held in listed
entities
Daniel Tillett
Qualifications
Experience
Interest in shares and options
Directorships held in
listed entities
Executive Director/Chair (appointed as a Non-Executive Director 28 June 2023,
appointed as Executive Director 24 August 2023, appointed as Chair 1
September 2024)
BA, MA (Natural Sciences), PhD (Cell Signalling)
Dr Smith has over 35 years of experience in the pharmaceutical and biotech
industry, with a strong focus on therapeutics, especially oncology. He has been
involved in projects at all stages from concept to phase III clinical studies and
drug approval. He was previously the CEO of private biotechnology company
Myrio Therapeutics, and publicly listed Australian companies Alchemia and
AMRAD. Prior to moving to Australia, Dr Smith co-founded and was Chief
Financial Officer of Onyvax Ltd, a cancer immunotherapy company based in
London. At the start of his career, he was a top-rated Pharmaceuticals Analyst
with UBS and HSBC, being involved in numerous transactions including
LSE/NASDAQ initial public offerings, fundraisings, and M&A.
His undergraduate degree, master’s and doctorate are from the University of
Cambridge. He is also currently a Director of Amala Therapeutics.
Personal & related party relevant interests:
- 440,019 options exercisable at $1.39, expiring 1/12/2028
None
CEO and Managing Director (appointed as CEO 22 November 2023, appointed
as Managing Director 1 September 2024)
BSc (HonsI), PhD (Molecular Genetics & Biochemistry)
Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private Australian
biotechnology company producing and selling world-leading DNA sequencing
software to the genomics industry. Nucleics SAAS (software as a service)
genomics tools are used in more than 30 countries and at over 250 companies
and research institutions. Dr Tillett was previously an Executive Director and
Chief Scientific Officer at Race from 17 September 2019 and 1 October 2019,
respectively and resigned from both roles on 21 March 2023. Dr Tillett was a
Senior Lecturer within the School of Pharmacy at La Trobe University where he
taught and researched in the areas of pharmacy, phage therapy, virology,
microbiology, bioinformatics and cancer. Dr Tillett’s PhD on the molecular
genetics and biochemistry of microcystin toxin production was awarded by the
University of New South Wales in 2000. He has more than 40 scientific
publications and granted patents in molecular biology, virology, microbiology,
genetics and biochemistry.
Personal & related party relevant interests:
- 17,267,615 Fully Paid Ordinary Shares, 2,448,342 Piggyback options
exercisable at $1.25, expiring 29/05/2026.
- 2,000,000 options exercisable at $2.65, expiring 29/11/2025
- 1,534,712 options exercisable at $1.45, expiring 29/11/2028
- 3,061,101 options exercisable at $4.25, expiring 29/11/2028
Simble Solutions Limited (Non‑Executive Director appointed 16 February 2022,
resigned 3 July 2023)
Tryptamine Therapeutics Limited (Non-Executive Director, appointed 8
November 2024)
5
6
Race Oncology Limited
Race Oncology Limited
Directors' report
30 June 2025
Serge Scrofani
Qualifications
Experience
Interest in shares and options
Directorships held in listed
entities
Megan Baldwin
Qualifications
Experience
Interest in shares and options
Directorships held in listed
entities
Non‑Executive Director (appointed 1 September 2024)
BSc (Hons), PhD (Biological Chemistry), MBA (Strategy)
Dr Serge Scrofani has more than 28 years’ experience in the healthcare sector,
working in global roles across research and strategy, and corporate and
business development. He served as Vice President of Strategy & Corporate
Development at CSL for 13 years where he played a pivotal role in multiple
strategic initiatives including the company’s global COVID-19 response and its
$US11.7 billion acquisition of Vifor Pharma AG. Prior to this, he led Business
Development for subsidiary CSL Behring, based in the United States (US).
Serge is currently CEO and Managing Director of FinCap Group Holdings Pty
Ltd, an Australian private investment firm. He is also a Board member of the
Burnet Institute and The Centre for Eye Research. After obtaining his PhD in
Structural Biology from La Trobe University, Serge undertook postdoctoral
research studies at The University of Melbourne and completed a Fulbright
postdoctoral fellowship at The Scripps Research Institute, La Jolla California. He
also holds an MBA from the Melbourne Business School.
Personal & related party relevant interests:
- 58,446 options exercisable at $2.050 expiring 25/11/2028
None
Non‑Executive Director (appointed 1 January 2025)
BSc (Hons), PhD (Medicine)
Dr Baldwin has more than 25 years of experience working on therapeutic drug
development programs for oncology and ophthalmic indications. She was the
Founder and Chief Innovation Officer of Opthea Limited (ASX:OPT;
NASDAQ:OPT). During her tenure of 10 years as CEO and Managing Director
of Opthea, the company’s lead asset was advanced through preclinical studies
to global Phase 3 registrational trials. Prior to Opthea, Dr Baldwin was
previously employed at Genentech (now Roche) as a researcher before moving
to Genentech’s commercial division. Dr Baldwin’s experience in oncology drug
development includes both preclinical and clinical investigation of inhibitors
targeting angiogenic factors involved in tumour growth and spread, as well as
management of competitive intelligence activities to support Genentech’s early
stage oncology programs. Dr Baldwin currently serves on the boards of Anaxis
Pharma,Gertrude Biomedical, and AusBiotech. She holds a PhD in Medicine
from the University of Melbourne, having conducted her doctoral studies at the
Ludwig Institute for Cancer Research.
None
Opthea Ltd (ASX/Nasdaq: OPT) Executive Director (from 1 February 2014 to 15
November 2024); Founder and Chief Innovation Officer (from 1 October 2023 to
1 July 2025);
Invex Therapeutics (from 1 February 2021 to 30 June 2024)
6
Annual Report 2025
7
Race Oncology Limited
Directors' report
30 June 2025
Mary Harney
Qualifications
Experience
Interest in shares and options
held at date of resignation
Directorships held in listed
entities
Phillip Lynch
Qualifications
Experience
Interest in shares and options
held at the date of resignation
Directorships held in listed
entities
Non‑Executive Chair (appointed as a Non-Executive Director 8 February 2021,
appointed as Chair 20 April 2023, resigned as Non-Executive Chair 1
September 2024)
IDP-C INSEAD, BSc, BA (Fine Arts), MAICD FIML
Ms Harney is the Director of specialist consulting firm Mary Harney Advisory
providing leadership, governance and strategic advice across innovation
industries such as health, biotech and agriculture. She currently also serves as
Chair of private Australian biotech Oncology One Pty Ltd, a cancer drug
discovery company, and Microbio Limited, a diagnostic development company.
Ms Harney was formerly the interim CEO of the $2bn Breakthrough Victoria
Fund, CEO of Royal Australasian College of Surgeons, CEO of Gardiner
Research Foundation, Chief Operating Officer (COO) and Director of Office of
Cancer Research for Peter MacCallum Hospital, and COO of Cerylid
Biosciences. Other former roles were with CSL, AMRAD, Bioproperties and
Royal Melbourne Hospital.
Personal & related party relevant interests:
- Mary Celicia Harney MMA Super Fund A/C - 24,570 Fully Paid Ordinary
Shares, 3,510 Piggyback options exercisable at $1.25, expiring 29/05/2026.
- Mary Celicia Harney - 110,392 options exercisable at $3.32, expiring
3/02/2028, and 139,516 options exercisable at $1.39, expiring 1/12/2028
All options lapsed on cessation of directorship.
None
Non‑Executive Director (appointed as a Non-Executive Director 1 June 2020,
appointed CEO & Managing Director 2 September 2020, ceased to be CEO &
Managing Director 1 February 2023, resigned as Non-Executive Director 1
September 2024)
BBus (Mktg), GAICD
Mr Lynch has a career spanning more than 30 years in the Asia Pacific region
with Johnson & Johnson. He is an experienced executive and board director,
with a diverse background across corporate development, strategy, financial
performance, marketing and governance. In his former role as Vice President of
Commercial Growth and Innovation Johnson & Johnson, 2016 ‑ 2019, Mr Lynch
partnered with the M&A team to drive the integration and growth of acquired
businesses. He retired from Johnson & Johnson in 2019 following the >$2b
acquisition and integration of a significant Japanese business. He is currently
the Chair of Consumer Health Products Australia.
Personal & related party relevant interests:
- 2,000,000 options exercisable at $2.65 expiring 29/11/2025
- Lynch Eventide Holdings Pty Ltd - Lynch Family A/C - 450,606 Fully Paid
Ordinary Shares, 64,371 Piggyback options exercisable at $1.25, expiring
29/05/2026
None
Information on officer holders and Key Management Personnel
Office Holders and Key Management Personnel (KMP) have been in their roles since the start of the financial year
to the date of this report unless otherwise stated.
Peter Webse
Qualifications
Experience
Company Secretary
BBus, FGIA, FCIS
Mr Webse has over 30 years' company secretarial experience and is the director
of Governance Corporate Pty Ltd, a company specialising in providing company
secretarial, corporate governance and corporate advisory services.
7
8
Race Oncology Limited
Race Oncology Limited
Directors' report
30 June 2025
Michelle Rashford
Qualifications
Experience
Interest in shares and options
held at the date of cessation of
employment
Directorships held in listed
entities
Chief Medical Officer (appointed 1 July 2023, resigned 23 April 2025)
BMedSci, MBBS
Dr Rashford is an internationally experienced biopharmaceutical executive and
former physician, with expertise in the successful development and
commercialisation of pharmaceuticals across oncology, virology, and
immunology. Her 30 years of drug development experience spans large
pharmaceuticals to smaller biotech companies and includes pre-clinical and
clinical development, medical and regulatory affairs, and drug
commercialisation. Prior to joining Race, Dr Rashford worked for Japanese
Pharmaceutical company Kyowa Kirin, where she was the Head of Global
Clinical Sciences. Prior to her role at Kyowa Kirin, Dr Rashford was the Senior
Vice President of Clinical Science at Adlai Nortye Biopharma, where she
successfully grew the US Clinical Development team and prepared for the
company’s Phase III trial. She has also held senior roles within global
pharmaceutical companies, including five years at Bristol-Myers Squibb and
close to 20 years at Roche in a variety of national and global clinical
development roles.
Personal & related party relevant interests:
- 1,116,083 options exercisable at $1.95, expiring 1/11/2028 (1,116,083 options
were cancelled following the cessation of employment)
None
Principal activities
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to
be at the heart of cancer care.
Race’s lead asset, RC220, is a small molecule anticancer agent. Bisantrene, which is the active pharmaceutical
ingredient in RC220, has a rich clinical history with demonstrated therapeutic benefits in both adult and paediatric
cancer patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect
and less cardiotoxicity over certain widely used cancer drugs such as doxorubicin.
Race is advancing RC220 to address the high unmet needs of patients across multiple oncology indications, with a
clinical focus on anthracycline combinations, where it hopes to deliver cardioprotection and enhanced anticancer
activity in solid tumours. Race is also exploring RC220 as a low intensity treatment for AML.
Race Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, University of North Carolina School
of Medicine, University of Wollongong and University of Newcastle, and is actively exploring strategic collaborations
and commercial arrangements to accelerate access to RC220 for patients with cancer across the world.
Outlook
At the time of writing, Race has advanced RC220 into the clinic in combination with doxorubicin in solid tumour
patients, to investigate its potential as an anticancer and cardioprotective agent. This trial is being undertaken in
Australia, Hong Kong and South Korea.
After a successful capital raise of $5 million in June 2024, via a strongly supported bonus option issue, Race is well
funded to undertake its company-sponsored Phase 1 trial in solid tumours. The Company looks forward to updating
shareholders on the continued progress of the Phase 1 trial in the coming months.
Overview of company performance
The table below sets out information about Race's earnings and movements in shareholder wealth for the past five
years up to and including the current financial year.
Net profit after tax ($'m)
Share price at year end ($)
Basic earnings per share (cents)
Total dividends (cents per share)
2025
$
(4.79)
1.18
(2.78)
-
2024
$
(13.82)
1.82
(8.40)
-
2023
$
(9.92)
1.23
(6.17)
-
2022
$
(11.20)
1.95
(7.28)
-
2021
$
(6.34)
3.67
(4.84)
-
8
Annual Report 2025
9
Race Oncology Limited
Directors' report
30 June 2025
Meetings of directors
During the financial year, 9 meetings of directors (including committees of directors) were held. Attendances by each
director during the year were as follows:
Directors' meetings
Peter Smith
Daniel Tillett
Serge Scrofani
Megan Baldwin
Mary Harney
Phillip Lynch
Number eligible to attend
Number attended
9
7
7
5
2
2
9
7
7
5
2
2
Operating results
The operating loss after providing for income tax amounted to $4,787,258 (2024: loss of $13,819,336); net cash used
in operating activities was $4,574,413 (2024: $9,545,579).
Dividends paid or recommended
There were no dividends paid, recommended or declared during the current or previous financial year.
Review of operations
On 2 July 2024, Race announced the appointment of Professor Daniel Von Hoff to Race’s Clinical Advisory Board.
Prof Daniel D Von Hoff, MD, FACP, FASCO, FAACR is an eminent physician and is the Executive Vice President of
the Molecular Medicine Divisions and Distinguished Professor at the Translational Genomics Research Institute in
Phoenix, Arizona, and City of Hope in Duarte, California. Professor Von Hoff is a pioneering world leader in
translational medicine, accelerating novel drug discoveries from the laboratory to cancer treatments in clinical trials,
where he has been involved in over 300 clinical studies. His major interest is in the development of new anticancer
agents, both in the clinic and in the laboratory. Early in his career, Prof Von Hoff worked with the original developers
of bisantrene, Lederle Laboratories, i
Share your feedback
Discover